Treatment of scabies

5% permethrin cream or oral ivermectin

- According to a meta-analysis of six randomised trials, including a total of about 600 patients with scabies, 5% permethrin cream seems to be more rapidly effective than oral ivermectin. Two weeks after treatment, the cure rates are similar. Uncertainties surround the risks associated with their use in women who are or may be pregnant, and in young children. Their transfer into breast milk should be taken into account.

Scabies is a contagious, parasitic skin infestation caused by the mite *Sarcoptes scabiei hominis*. It often manifests as intense itching which is worse at night, accompanied by skin lesions affecting in particular the interdigital spaces, while most often sparing the head and neck (1). Parasitological examination of a skin sample is sometimes useful for diagnosis in atypical forms (1).

Two drugs are used as first-line treatment of scabies: permethrin (a pyrethroid insecticide) as a 5% cream applied twice, at an interval of one or two weeks, and ivermectin taken as a single oral dose of 200 mcg/kg (2,3). Ivermectin 1% lotion for topical application to the skin is also an option, but as of early 2019, it is neither available nor authorised in this situation in France (4).

A systematic review conducted by a Cochrane Group, updated in 2017, identified randomised trials which compared these treatments in patients with scabies (5).

Similar efficacy with permethrin cream or oral ivermectin. In most of the studies identified, the diagnosis of scabies was not confirmed by parasitological examination (5). Depending on the trial, cure was defined as an improvement in pruritus, the absence of new lesions, or a negative parasitological examination (5).

According to a meta-analysis of six trials in a total of 613 patients, 5% permethrin seemed to be more rapidly effective than oral ivermectin. One week after treatment, about 65% of patients in the permethrin groups were considered cured, versus 40% in the oral ivermectin groups (5). Two weeks after treatment, about 70% of patients were considered cured, with no difference between the groups (a)(5).

According to three trials in a total of 482 patients, the efficacy of topical application of a 1% ivermectin lotion seemed to be similar to that of 5% permethrin cream or oral ivermectin (5).

Young children, pregnant or breastfeeding women: use with caution, given the uncertainties. Permethrin carries a risk of rare cutaneous adverse effects, including pruritus, redness, burning sensation, dry skin, oedema and hypersensitivity reactions (2,5). Its use is authorised in children aged 2 months and older. However, one epidemiological study, in 2006, raised the possibility of an increased risk of acute leukaemia after use of permethrin in children (6). No particular safety signal has been identified in the unborn child when a pregnant woman uses permethrin (2). Permethrin is transferred into breast milk, and its application to the breasts creates a risk of ingestion by the breastfeeding baby. It is therefore advisable that women suspend breastfeeding during permethrin treatment (2).

The adverse effects of oral ivermectin are rare and in general not serious, including: headache, dizziness, blurred vision, diarrhoea, vomiting, abdominal pain, bone and joint pain, and haematuria (3,5). Ivermectin 1% lotion carries a risk of rare cutaneous adverse effects, but we have less experience with its use (4,5). The data on pregnant women exposed to ivermectin have not revealed any particular risk for the unborn child (6,7). Fetal malformations have been observed after administration of ivermectin to animals (6,7). Ivermectin is transferred into breast milk and has not been evaluated in children weighing less than 15 kg, which justifies suspending breastfeeding to allow time for elimination of the drug and its metabolites (3,5).

In practice In patients with scabies, topical application of 5% permethrin cream and oral ivermectin have a similar harm-benefit balance. 5% permethrin cream seems to be more rapidly effective, but its application is sometimes difficult in practice. In pregnant women, it seems preferable to use permethrin and to avoid ivermectin. In breastfeeding women, it is advisable to temporarily suspend breastfeeding during treatment with ivermectin or permethrin. In infants weighing less than 15 kg, permethrin is the main option to consider, after making sure that the skin lesions are actually symptoms of scabies.